ClaremontBio is dedicated to providing affordable, user-friendly devices that simplify and revolutionize molecular diagnostics and bioscience research. We specialize in products for fast cell lysis, genomic DNA extraction, and real-time DNA detection. Our goal is to eliminate complex protocols and additional lab equipment, making research and diagnostics more efficient and accessible. We serve a wide range of industries, focusing on innovation, cost-effectiveness, and ease of use, with the vision to lead the next generation of technologies in molecular diagnostics and genomics-based research.
July 2023: Miniature, Low-Power, Disposable Device for Mechanical Cell DisruptionFunder: Bill & Melinda Gates Foundation The grant was awarded under the topic of Enterics, Diagnostics, Genomics & Epidemiology. ClaremontBio plans to develop an economical, disposable, easy-to-use lyser suitable for use with molecular testing in the field.
April 2021: Automated Ultra-Long DNA and RNA Extraction for Long-read Sequencing ApplicationsFunder: NIH - National Institute of General Medical Sciences Claremont BioSolutions has been awarded a PHASE IIB SBIR grant to support the development of a novel automated technology for DNA and RNA extraction. The grant, totaling over $2 million across two years, aims to address challenges in long DNA and RNA sample preparation for third-generation sequencing. This innovative system will streamline the process, enabling users to collect high-quality DNA or RNA in just 30 minutes. By combining lysis, nucleic acid binding, and isolation, the technology overcomes limitations in current methods, providing a faster and more cost-effective solution for genomics research.
April 2017: Suitability of Low Cost Nucleic Acid Sample Preparation Devices to Meet Resource Poor Setting RequirementsFunder: Bill & Melinda Gates Foundation Claremont BioSolutions has won a challenge grant from The Bill and Melinda Gates Foundation under the grant topic Support Innovative Technology Solutions to validate novel, low cost sample preparation technologies for use in low resource settings.
July 2012: A Fully Integrated Assay and Platform for Detecting Clostridium difficileFunder: NIAID (National Institute of Allergy and Infectious Diseases) Claremont BioSolutions has received a $3 million Phase II SBIR grant from NIH/NIAID to develop a bench-top device for detecting Clostridium difficile. This collaborative project involves partners from Keck Graduate Institute, PATH, and Beth Israel Deaconess Medical Center. The new device will enable rapid, near-patient diagnosis of C. difficile, a leading hospital-acquired infection. By reducing time to treatment and monitoring contamination in healthcare facilities, the technology aims to improve patient outcomes and reduce costs. ClaremontBio’s CEO, Dr. Gary Blackburn, emphasized that this grant follows the success of their Phase I SBIR award and validates their innovative approach to sample preparation and diagnostics.
Patent 11,718,812 - System, Compositions and methods for disaggregation of biological tissue samples - Issued: August 8, 2023
Patent CA 2,711,854 - System, Apparatus and Method for Material Preparation and/or Handling - Issued: March 21, 2023
Patent 11,479,747 - ARRAYED LYSER AND HOMOGENIZER SYSTEMS WITH MULTIPLE AGITATOR DEVICES - Issued: October 25, 2022
Patent 11,473,049 - Compositions and methods for disaggregation of biological tissue samples - Issued: October 18, 2022
Patent 11,286,447 - Compositions and methods for disaggregation of biological tissue samples - Issued: March 29, 2022
Patent 10,801,001 - Compositions and methods for disaggregation of biological tissue samples - Issued: October 13, 2020
Patent 10,428,301 - System, Apparatus and Method for Material Preparation and/or Handling - Issued: October 1, 2019
Patent D829,339 - Homogenizer Rack - Issued: September 25, 2018
Patent HK 1171052 - Capture and elution of bio-analytes via beads that are used to disrupt specimens - Issued: August 3, 2018
Patent 9,873,860 - Capture and elution of bio-analytes via beads that are used to disrupt specimens - Issued: January 23, 2018
Patent EP 2446047 - Capture and elution of bio-analytes via beads that are used to disrupt specimens - Issued: October 18, 2017
Patent 9,428,725 - Compositions and Methods for Capture and Elution of Biological Materials via Particulates - Issued: August 30, 2016
Patent 9,358,540 - Systems and Devices for Isothermal Biochemical Reactions and/or Analysis - Issued: June 16, 2016
Patent 9,260,475 - Capture and elution of bio-analytes via beads that are used to disrupt specimens - Issued: February 16, 2016
Patent JP 5711227 - Capture and elution of bio-analytes via beads that are used to disrupt specimens - Issued: April 30, 2015
Patent JP 5663311 - System, Apparatus and Method for Material Preparation and/or Handling - Issued: February 4, 2015
Patent 8,784,736 - Systems and Devices for Isothermal Biochemical Reactions and/or Analysis - Issued: July 22, 2014
Patent 8,153,064 - Systems and Devices for Biochemical Reactions and/or Analysis - Issued: April 4, 2012
Claremont BioSolutions LLC and Gold Colloid Announce Distribution Agreement September 8, 2023
Claremont BioSolutions LLC, a life science tools company offering novel rapid sample preparation and test development products, and Gold Colloid, Co., a point-of-care (POC) test development company, today announced a distribution agreement for Gold Colloid’s gold nanoparticles.
The agreement will allow Claremont BioSolutions to distribute Gold Colloid’s gold nanoparticles to its customers in the life sciences, medical, and environmental testing markets. Gold nanoparticles are used in a variety of applications, including diagnostics, biosensing, and bioimaging.
“We are excited to partner with Claremont BioSolutions to distribute our gold nanoparticles,” said Daniel Levenson, President of Gold Colloid. “Claremont BioSolutions has a strong track record of success in the life sciences market, and we believe this partnership will help us to reach a wider audience of customers.”
“We are pleased to partner with Gold Colloid to distribute their gold nanoparticles,” said Dr. Robert Doebler, President of Claremont BioSolutions. “We have been using Gold Colloid Company’s high-quality 40nm gold nanoparticles for over 5 years. We feel this partnership will help us to meet the needs of our many R&D customers who appreciate highly monodisperse gold nanoparticles in lateral flow assay development.”
Robert Doebler, President, Claremont BioSolutions can be reached at [email protected]
Daniel Levenson, President, Gold Colloid, Co. can be reached at [email protected]
IncellDx, Inc. Signs Exclusive License with Claremont BioSolutions to Commercialize Novel Liquid-Based Biopsy Technology April 14, 2015
Companies’ Combined Technology Produces a “Universal” Sample from Liquid, Fresh or Formalin-Fixed Paraffin Embedded (FFPE) Tissue for Multiplexed Cell Analysis by Flow or Image Cytometry
MENLO PARK, Calif., Apr 14, 2015 (BUSINESS WIRE) -- IncellDx, Inc. announced today the signing of a worldwide, exclusive license and supply agreement with Claremont BioSolutions (Upland, CA) to couple their enzyme-free tissue homogenization technology with IncellDx’s patented reagents. The combination forms a sample preparation system called IncellPrep™ Liquid Biopsy, to prepare “universal” cell suspensions formed from either fresh or FFPE tissue. The IncellPrep Liquid Biopsy can be used with IncellDx reagents for multiplex detection of protein, mRNA, and DNA in intact cells by flow or image cytometry.
Bruce Patterson, M.D., CEO of IncellDx commented, “This exciting marriage of technologies circumvents the problems of using different technologies for different specimen types by creating a 'Universal Specimen.' This will allow IncellDx to compete in the histology and immunohistochemistry (IHC) space with our single cell multiplex technology in cancer and infectious disease.”
“The IncellDx liquid biopsy technology is likely to have a major impact in cancer diagnostics and ClaremontBio is pleased that our unique cell dispersion disposables will help to make that possible,” commented Gary Blackburn, Ph.D., CEO of Claremont BioSolutions.
Claremont BioSolutions, LLC Announces Reagent Supply Agreement with SeraCare Life Sciences March 14, 2014
Upland, CA - Claremont BioSolutions, LLC, pioneer of rapid sample preparation technologies, today announced an agreement with SeraCare Life Sciences to supply synthetic stool matrix for use in its quality control products. ClaremontBio has developed products for sample preparation of difficult-to-handle samples such as sputum and stool and has particular expertise in developing biologically relevant reagent formulations that mimic these sample types.
SeraCare recently released its new ACCURUN® 501 C. difficile Control – the company’s first molecular control product targeting hospital acquired infections. C. difficile testing is performed by detecting bacterial DNA isolated from stool samples, an area that ClaremontBio has been pursuing in research supported by the National Institutes of Health over the past four years.
Under the agreement, Claremont BioSolutions will supply its proprietary synthetic stool formulations to SeraCare for use in its products and for the development of future products.
Claremont BioSolutions Announces Strategic Investment and Technology Development Agreement with IQT October 17, 2012
Partnership with IQT will accelerate commercialization of Prep-on-a-Chip technology
Upland, CA – October 3, 2012 – Claremont BioSolutions, LLC, pioneer of micromotor-based rapid sample preparation devices, today announced a strategic partnership and technology development agreement with In‐Q‐Tel (IQT) to accelerate commercialization of its Prep-on-a-Chip sample preparation platform. IQT, based in Arlington, VA, is the independent strategic investment firm that identifies, adapts, and delivers, technologies that support the missions of the US intelligence community.
Claremont BioSolutions has harnessed the mechanical energy of micromotors used in the cell phone industry to create entirely disposable sample preparation devices that efficiently lyse any cell type, and simultaneously extract DNA or RNA. The battery-powered devices are currently hand-operated using a syringe or pipettor to transport the sample through a small chamber where cells are lysed, and nucleic acids are extracted in less than five minutes.
“The In-Q-Tel investment will aid us in our mission to multiplex and automate the handling of the devices, completing our development of the Prep-on-a-Chip™ platform” Gary Blackburn, CEO, said in a statement. “The technology is unique in that it can be readily integrated into disposable diagnostic cartridges, making POC and field-use of molecular diagnostics a realizable goal.”
“Claremont BioSolutions has taken an innovative approach to nucleic acid extraction,” said Syd Ulvick, Senior Vice President in charge of Physical and Biological Technologies at IQT, “We believe that further development of this technology will provide valuable capabilities for both the public and private sector.”
Claremont BioSolutions Names BioQuote as its Distributor in the UK and Ireland December 1, 2011
Claremont BioSolutions, LLC announced today that it has reached an agreement with Bioquote Limited for the distribution of its products for sample preparation, DNA isolation, and protein purification in the United Kingdom and Ireland. The agreement extends ClaremontBio’s reach into European markets and expands the customer base of their novel products for sample preparation.
ClaremontBio develops, manufactures, and markets next‐generation cell lysis, DNA extraction, and His‐tagged protein purification kits and columns. Bioquote is a distributor of life science products, servicing all of the U.K., Ireland, and Europe. Bioquote will offer ClaremontBio’s products to customers in various academic and bioscience communities. The first products to be marketed are ClaremontBio’s Omnilyse® lysis kits and PureLyse® DNA extraction kits.
“We are excited to expand our marketing efforts to Europe,” said Gary Blackburn, ClaremontBio’s Chief Executive Officer. “We are committed to offering our rapid sample preparation solutions to customers worldwide and we believe that BioQuote shares our desire to provide quality products and quality customer service. Our partnership will expand as ClaremontBio announces additional new products in the next few months.”
Claremont BioSolutions and Funakoshi Announce Distribution Agreement for Japan December 14, 2011
Claremont BioSolutions, LLC announced today that it has reached an agreement with Funakoshi for the distribution of its products for sample preparation, DNA isolation, and protein purification in Japan. The agreement reflects ClaremontBio’s expansion of its marketing efforts into Asia and Europe.
Funakoshi is a leading distributor of life science products and research tools to the Japanese market. Funakoshi will offer ClaremontBio’s products to customers in various academic and bioscience communities. ClaremontBio develops, manufactures, and markets next‐generation cell lysis, DNA extraction, and His‐tagged protein purification kits and columns. The first products to be marketed are ClaremontBio’s OmniLyse® lysis kits and PureLyse® DNA extraction kits.
“We are pleased to partner with Funakoshi, a long‐time leader in the sale of tools to the research market in Japan” said Gary Blackburn, ClaremontBio’s Chief Executive Officer. “Our rapid sample preparation solutions have been well received in the US and we are committed to offering our products to customers worldwide.”
